资讯内容 Content

2022年ASCO大会乳腺癌领域的中国好声音
作者:肿瘤瞭望 时间:2022/6/6 14:39:08    加入收藏
 关键字:乳腺癌 
编者按:2022年美国临床肿瘤学会年会(2022 ASCO)将于当地时间6月3~7日在芝加哥以线上、线下会议的形式举行。美国临床肿瘤学会(ASCO)年会是世界上规模最大、学术水平最高、最具权威的临床肿瘤学会议,汇集了众多世界一流的肿瘤学专家。本文汇总了本届ASCO大会乳腺癌领域的中国好声音(排名不分先后,未包括e-poster),如有遗漏,还请您后台留言指出。
 
Poster Session:Breast Cancer—Local/Regional/Adjuvant
 
Efficacy and safety of initial five years of adjuvant endocrine therapy in postmenopausal hormone receptor-positive breast cancer:A systematic review and network meta-analysis.
 
绝经后激素受体阳性乳腺癌初始5年辅助内分泌治疗的有效性和安全性:一项系统综述和网络荟萃分析。
 
讲者:Hao Liao|北京大学肿瘤医院
 
摘要号:535|Poster:307
 
Ovarian function suppression is not indispensable in patients with early breast cancer who are older than age 40.
 
在40岁以上的早期乳腺癌患者中,卵巢功能抑制并不是必不可少的。
 
讲者:Jianqiao Xian,MD|中山大学肿瘤防治中心
 
摘要号:539|Poster:311
 
Peripheral lipidomics analyses with ensemble machine learning predict response to neoadjuvant therapy in breast cancer.
 
使用集成机器学习进行外周脂质组学分析可预测乳腺癌新辅助治疗的反应。
 
讲者:王佳妮|中国医学科学院肿瘤医院
 
摘要号:582|Poster:353
 
Primary analysis of MUKDEN 01:A multicenter,single-arm,prospective,phase 2 study of neoadjuvant treatment with pyrotinib and letrozole plus dalpiciclib in triple-positive breast cancer.
 
一项多中心、单组、前瞻性的2期研究(MUKDEN 01研究)初步分析:在三阳性乳腺癌中使用吡咯替尼和来曲唑联合达匹西利进行新辅助治疗。
 
讲者:牛楠|中国医科大学附属盛京医院
 
摘要号:588|Poster:359
 
Anlotinib plus tislelizumab combined with chemotherapy as neoadjuvant treatment in triple-negative breast cancer:A prospective,single-arm,open-label phase II study.
 
一项前瞻性、单臂、开放标签的Ⅱ期研究:安罗替尼+替雷利珠单抗联合化疗作为三阴性乳腺癌的新辅助治疗策略
 
讲者:罗静|四川省人民医院
 
摘要号:TPS618|Poster:383b
 
Phase II neoadjuvant pyrotinib combined with epirubicin and cyclophosphamide followed by docetaxel in HER2-low–expressing and HR-positive early or locally advanced breast cancer(PILHLE-001):A single-arm trial.
 
一项单臂Ⅱ期试验(PILHLE-001):新辅助阶段吡咯替尼联合表柔比星和环磷酰胺序贯多西紫杉醇治疗HER2低表达和HR阳性的早期或局部晚期乳腺癌。
 
讲者:Yuan Xia|中山大学孙逸仙纪念医院
 
摘要号:TPS620|Poster:384b

Poster Session:Breast Cancer—Metastatic
 
Pyrotinib in combination with metronomic oral vinorelbine in patients with HER2-positive advanced breast cancer who had failed prior trastuzumab-based therapy:A single-center,single-arm,prospective phase 2 study.
 
一项单中心、单臂、前瞻性Ⅱ期研究:吡咯替尼联合节拍口服长春瑞滨治疗既往经曲妥珠单抗治疗失败的HER2阳性晚期乳腺癌患者。
 
讲者:郝春芳|天津医科大学肿瘤医院
 
摘要号:1033|Poster:411
 
Pyrotinib monotherapy or pyrotinib in combination with capecitabine could significantly prolong progression-free survival and overall survival in patients with HER2-positive metastatic breast cancer.
 
吡咯替尼单药治疗或吡咯替尼联合卡培他滨可显著延长HER2阳性转移性乳腺癌患者的无进展生存期和总生存期。
 
讲者:管秀雯|中国医学科学院肿瘤医院
 
摘要号:1034|Poster:412
 
Pyrotinib plus nab-paclitaxel in patients with HER2-positive advanced or metastatic breast cancer:A multicenter,single-arm,open-label phase 2 trial.
 
一项多中心、单臂、开放标签的2期试验:吡咯替尼加白蛋白结合型紫杉醇治疗HER2阳性晚期或转移性乳腺癌患者
 
讲者:李欢|辽宁省肿瘤医院
 
摘要号:1035|Poster:413
 
Updated results and biomarker analyses from the phase I trial of A166 in patients with HER2-expressing locally advanced or metastatic solid tumors.
 
A166治疗HER2表达局部晚期或转移性实体瘤患者的Ⅰ期试验结果更新和生物标志物分析。
 
讲者:胡夕春|复旦大学肿瘤医院
 
摘要号:1037|Poster:415
 
Early clinical safety and pharmacokinetics data of DZD1516,an BBB-penetrant selective HER2 inhibitor for the treatment of HER2-positive metastatic breast cancer.
 
DZD1516的早期临床安全性和药代动力学数据,一种BBB渗透选择性HER2抑制剂,用于治疗HER2阳性转移性乳腺癌。
 
讲者:胡夕春|复旦大学肿瘤医院
 
摘要号:1038|Poster:416
 
Pyrotinib-based therapy for patients with HER2-positive breast cancer:A multicenter,real-world study.
 
一项多中心真实世界研究:HER2阳性乳腺癌患者基于吡咯替尼的治疗
 
讲者:Haoqi Wang|河北医科大学第四医院
 
摘要号:1040|Poster:418
 
Chemotherapy shows better efficacy than endocrine therapy in patients with metastatic breast cancer with heterogeneous estrogen receptor expression.
 
在具有异质雌激素受体表达的转移性乳腺癌患者中,化疗显示出比内分泌治疗更好的疗效。
 
讲者:Yizhao Xie|复旦大学附属肿瘤医院
 
摘要号:1050|Poster:428
 
Clinical value of next-generation sequencing in endocrine therapy for advanced hormone receptor–positive/HER2-negative breast cancer.
 
二代测序在晚期激素受体阳性/HER2-乳腺癌内分泌治疗中的临床价值
 
讲者:吕丹|中国医学科学院肿瘤医院
 
摘要号:1062|Poster:440
 
Dalpiciclib in combination with letrozole/anastrozole or fulvestrant in HR+/HER2-advanced breast cancer:A phase Ib study.
 
一项Ib期研究:Dalpiciclib联合来曲唑/阿那曲唑或氟维司群治疗HR+/HER2-晚期乳腺癌
 
讲者:张清媛|哈尔滨医科大学附属肿瘤医院
 
摘要号:1066|Poster:444
 
Hormone therapy(HT)or capecitabine(CAP)as maintenance therapy following the first-line chemotherapy in HR+/HER2-ABC/MBC:Secondary endpoint adverse effects(AEs)and toxicity report of OVERSTEP Trial(ZJCH15001/CBCSG 035).
 
OVERSTEP试验的次要终点不良反应(AE)和毒性报告(ZJCH15001/CBCSG 035):HR+/HER2-ABC/MBC一线化疗后激素治疗(HT)或卡培他滨(CAP)维持治疗
 
讲者:黄健|浙江省肿瘤医院
 
摘要号:1068|Poster:446
 
The safety,tolerability,and preliminary antitumor activity of sitravatinib plus tislelizumab in patients with locally recurrent or metastatic triple-negative breast cancer.
 
sitravatinib+tislelizumab在局部复发或转移三阴性乳腺癌患者中的安全性、耐受性和初步抗肿瘤活性
 
讲者:范蕾|复旦大学附属肿瘤医院
 
摘要号:1070|Poster:448
 
Apatinib combined with chemotherapy versus single chemotherapy in HER-2 negative advanced breast cancer:A randomized,controlled,open-label phase II study.
 
一项随机、对照、开放标签的Ⅱ期研究:阿帕替尼联合化疗对比单纯化疗治疗HER2-晚期乳腺癌
 
讲者:陈占红|浙江省肿瘤医院
 
摘要号:1072|Poster:450
 
A phase 3,multicenter,open,randomized controlled clinical study of gemcitabine plus capecitabine versus gemcitabine plus carboplatin in the first-line treatment for advanced triple-negative breast cancer.
 
一项Ⅲ期、多中心、开放的随机对照研究:吉西他滨加卡培他滨对比吉西他滨加卡铂一线治疗晚期三阴性乳腺癌。
 
讲者:Xiaodong Liu|天津医科大学肿瘤医院
 
摘要号:1077|Poster:455
 
Genomic landscape and peripheral blood biomarkers of advanced triple-negative breast cancer treated with immune checkpoint blockade:An exploratory analysis of the TQB2450-Ib-07 trial.
 
TQB2450-Ib-07试验的探索性分析:免疫检查点阻断治疗晚期三阴性乳腺癌的基因组全景和外周血生物标志物
 
讲者:Yiqun Han|中国医学科学院肿瘤医院
 
摘要号:1080|Poster:458
 
Eribulin mesylate versus eribulin plus anlotinib in patients with advanced or metastatic breast cancer:Results of a phase II study.
 
对比单药艾立布林与艾立布林+安罗替尼在晚期或转移性乳腺癌患者中的治疗效果
 
讲者:Liping Liu|湖南省肿瘤医院
 
摘要号:1094|Poster:471
 
A multiple center,open-label,single-arm,phase II clinical trial of MRG002,an HER2-targeted antibody-drug conjugate,in patients with HER2-low expressing advanced or metastatic breast cancer.
 
一项多中心、开放标签的单臂Ⅱ期临床试验:MRG002(一种HER2靶向抗体药物偶联物)在HER2低表达晚期或转移性乳腺癌患者中的疗效。
 
讲者:江泽飞|解放军总医院第五医学中心
 
摘要号:1102|Poster:479
 
Patient-reported outcomes for measuring the quality of life in advanced breast cancer treated with third-line and beyond chemotherapy-based regimens:A national cross-sectional study.
 
一项全国性横断面研究患者报告结局的测定:晚期乳腺癌患者接受三线级以上化疗方案治疗后的生活质量
 
讲者:管秀雯|中国医学科学院肿瘤医院
 
摘要号:1103|Poster:480
 
A novel oral paclitaxel and HM10381(oraxel)-treated metastatic breast cancer:A phase I study(KX?ORAX?CN-007).
 
Ⅰ期研究(KX-ORAX CN-007):新的口服紫杉醇和HM10381(oraxel)治疗转移性乳腺癌的效果
 
讲者:Tao Qin|中山大学孙逸仙纪念医院
 
摘要号:1104|Poster:481

点击排行 Top Hits

 
关于本站 | 设为首页 | 加入收藏 | 站长邮箱 | 友情链接 | 版权申明

肿瘤瞭望 版权所有  2014-2019 ioncol.com  All Rights Reserved